Bliss GVS Pharma Limited has informed the Exchange regarding Board meeting held on May 12, 2025.
BLISSGVS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.4 pts less than Nifty Microcap 250 and 1.7 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Bliss GVS Pharma's board approved audited standalone and consolidated results for Q4 and FY ended March 31, 2025, with auditors issuing an unmodified (clean) opinion. Standalone revenue rose to ₹667.20 crore from ₹605.46 crore (~10% growth), while net profit grew to ₹68.97 crore from ₹50.64 crore in FY24, though FY24 was weighed down by a one-time ₹41.09 crore impairment of subsidiary investments. Consolidated revenue reached ₹809.73 crore with net profit of ₹90.26 crore. The board recommended a final dividend of ₹0.50 per share (50% on face value of ₹1), subject to shareholder approval at the 40th AGM on July 31, 2025. The company also approved the sale of its 51% step-down subsidiary Greenlife Bliss Healthcare Ltd (Nigeria) to the existing non-controlling shareholder for USD 13 lakh, a related-party transaction. Additionally, up to 12.1 lakh sweat equity shares will be issued to the MD and a Vice President at ₹148.72 per share.
The clean audit opinion and steady dividend are positive signals, but the underlying core profit (excluding last year's one-time impairment) has actually declined, and the sale of the Nigeria step-down subsidiary to a related party may raise governance questions. Sweat equity issuance will lead to some shareholder dilution, though the small size (about 1.1% of capital) limits the impact.